ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr
December 18, 2024Ascletis Pharma Inc. announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity. -
First HBV patient dosed in phase IIa clinical trial of ASC22
August 19, 2020Ascletis Pharma announces the dosing of the first HBV patient in Phase IIa clinical trial of ASC22, which is a first-in-class, subcutaneously administered PD-L1 antibody. -
Results from First Clinical Study Using Danoprevir to Treat Naive and Experienced COVID-19 Patients
March 25, 2020Ascletis Pharma Inc. (HKEX code: 1672) announces today the first clinical study using Ganovo®(danoprevir) to treat naive and experienced COVID-19 patients was published in medRxiv. -
Ascletis Pharma to develop Alphamab’s viral diseases drug in China
January 16, 2019Ascletis Pharma has signed an exclusive licensing agreement with Suzhou Alphamab to develop an investigational candidate, KN035, for the treatment of viral diseases such as hepatitis B in Greater China.... -
WHO HCV Guidelines recommends Ascletis' Ravidasvir
August 10, 2018Ravidasvir is a next-generation, best-in-class and pan-genotypic HCV NS5A inhibitor with a high genetic barrier to resistance
Pharma Sources Insight January 2025
